Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.44 |
| ▸ | NQO2 | P16083 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26813105 | 0.88 | HSP90AA1 (0.39) | CRHR1NQO2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL26813125 | 0.84 | GAA (0.51) | NQO2SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL24287257 | 0.81 | SMN1; SMN2 (0.50) | CRHR1NQO2SMN1; SMN2KDM4EGAA | |
| SCHEMBL26813123 | 0.80 | ALDH1A1 (0.46) | NQO2SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL8024194 | 0.73 | NQO2 (0.44) | NQO2SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL789181 | 0.72 | KDM4E (0.51) | NQO2KDM4EMEN1KMT2A | |
| SCHEMBL13150847 | 0.70 | MAPT (0.53) | NQO2SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL5845741 | 0.70 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL26813109 | 0.70 | MAPT (0.40) | — | |
| SCHEMBL26817460 | 0.68 | KDM4E (0.60) | KDM4EMEN1KMT2AGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CRHR1 4583/4885NQO2 1095/4885SMN1; SMN2 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.